CalciMedica (NASDAQ:CALC) versus Sanofi (NASDAQ:SNY) Head to Head Comparison

CalciMedica (NASDAQ:CALC) and Sanofi (NASDAQ:SNY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for CalciMedica and Sanofi, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	0	0	3	0	3.00
Sanofi	0	3	1	0	2.25

CalciMedica currently has a consensus price target of $20.67, indicating a potential upside of 400.40%. Sanofi has a consensus price target of $55.00, indicating a potential upside of 8.65%. Given CalciMedica’s stronger consensus rating and higher possible upside, research analysts plainly believe CalciMedica is more favorable than Sanofi.

Insider & Institutional Ownership

10.0% of Sanofi shares are held by institutional investors. 53.3% of CalciMedica shares are held by company insiders. Comparatively, 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

CalciMedica has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500.

Earnings and Valuation

This table compares CalciMedica and Sanofi’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$34.36 million	($2.15)	-1.92
Sanofi	$46.70 billion	2.75	$5.84 billion	$1.99	25.44

Sanofi has higher revenue and earnings than CalciMedica. CalciMedica is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CalciMedica and Sanofi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-143.95%	-102.67%
Sanofi	10.52%	26.25%	15.35%

Summary

Sanofi beats CalciMedica on 8 of the 13 factors compared between the two stocks.

About CalciMedica

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.